Company Of The Day: Johnson & Johnson

JNJ: Johnson & Johnson logo
Johnson & Johnson


Johnson & Johnson (NYSE:JNJ) is negotiating partnership deals with two unnamed Chinese companies, per a report from the Financial Times.

So What?

Relevant Articles
  1. Should You Buy Johnson & Johnson Stock At $177?
  2. Here’s Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether
  3. This Semiconductor Chip Company Is Likely To Offer Better Returns Over Johnson & Johnson Stock
  4. Does Johnson & Johnson Stock Have More Upside?
  5. Here’s Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock
  6. Despite Its Mixed Q4 Johnson & Johnson Stock May See Higher Levels

U.S. pharma companies have been increasingly interested in licensing drugs from Chinese biotech players, who are seeing a lot of innovation, driven by higher public and private investments. Moreover, J&J’s past experience with Chinese collaborations has been good. Last week, the U.S. FDA approved Carvykti, a cancer drug that J&J developed along with China’s Legend Biotech.

See Our Complete Analysis For Johnson & Johnson

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Mar 2022
MTD [1]
YTD [1]
Total [2]
 JNJ Return 5% 1% 49%
 S&P 500 Return -4% -12% 88%
 Trefis MS Portfolio Return -5% -15% 236%

[1] Month-to-date and year-to-date as of 3/8/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates